Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
ARS Pharmaceuticals, Inc. (SPRY) had Return on Equity of -36.17% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$28.09M |
|
$-41.42M |
|
$6.15M |
|
$21.93M |
|
$69.55M |
|
$-41.47M |
|
$0.06M |
|
$-41.40M |
|
$-41.40M |
|
$-41.32M |
|
$-41.32M |
|
$-41.32M |
|
$-41.32M |
|
$-41.47M |
|
$-42.05M |
|
98.57M |
|
98.57M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$284.90M |
|
$2.46M |
|
$42.76M |
|
$327.65M |
|
$39.15M |
|
$168.51M |
|
$174.25M |
|
$213.39M |
|
$114.26M |
|
$99.81M |
|
$114.26M |
|
99.29M |
|
| Cash Flow Statement Financials | |
$-170.87M |
|
$56.77M |
|
$104.60M |
|
$50.82M |
|
$41.32M |
|
$-9.50M |
|
$22.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.28 |
|
-- |
|
-- |
|
0.60 |
|
1.47 |
|
78.09% |
|
-147.63% |
|
-147.63% |
|
-- |
|
-147.41% |
|
-147.47% |
|
$-171.21M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
0.74 |
|
1.11 |
|
81.22 |
|
|
Return on Equity |
-36.17% |
-41.40% |
|
-12.61% |
|
-14.61% |
|
$1.15 |
|
$-1.74 |
|
$-1.73 |
|